A randomized, controlled, crossover trial published in 2006 called the 5-Nations Trial similarly showed that CSII
treatment in individuals with type 1 diabetes resulted in lower HbAlc, lower mean blood glucose level, less fluctuation in glucose levels, and higher quality of life than MDI (Diabet.
Previous studies have demonstrated that CSII
may improve treatment satisfaction among people with type 2 diabetes and may thereby improve glycemic control or willingness to switch to insulin," said John Pickup, MD, professor of Diabetes and Metabolism at the Kings College London School of Medicine.
com navigate the complicated business landscape in China and are proud that the company has chosen CSII
as its partner," said Mr.
Under the terms of the agreement, CSII
will sublicense Open Solutions' relational enterprise data processing solutions and integrated strategic products, serving as a nonexclusive distributor to China, Hong Kong and Macau.
ADA Poster Presentation Details Title: "Recombinant Human Hyaluronidase Pretreatment of CSII
Cannula Sites Provides Comparable Glycemic Control with Reduced Hypoglycemia in T1DM Compared to Usual CSII
" Abstract #: 85-LB, June 15, 2014, 12:00 p.
PaQ is a simple CSII
device with demonstrated ability to safely and effectively address many of the issues that make daily injection therapy a challenge for so many people with diabetes," said James Peterson, founder and CEO, CeQur.
This system eliminates the need for daily insulin injections, does not require people with diabetes to be tethered to a conventional insulin pump via tubing and is designed to make CSII
easier to prescribe, learn and use.
Blum's online resource will provide education, user tips, and strategies in support of all CSII
and CGM systems - on a user-friendly web-based platform.